Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies, Argos Therapeutics to Collaborate on Patient Response to Immunotherapies

NEW YORK (GenomeWeb) – Immuno-oncology firm Argos Therapeutics has announced a research agreement with Seattle-based Adaptive Biotechnologies to study patient response to investigational immunotherapies.

Adaptive combines high-throughput sequencing and bioinformatics to profile T- and B-cell receptors. Under the terms of the agreement, the Seattle-based firm will use its ImmunoSeq immune profiling assay to characterize immune response to Argo's lead product candidate, AGS-003, for metastatic renal cell carcinoma, non-small cell lung cancer, and bladder cancer. The companies will also partner on profiling genetic signatures in response to an investigational treatment for HIV or AIDS.

"Adaptive is our preferred partner because of their established expertise in offering high-throughput immune receptor repertoire characterization," Argos CSO Charles Nicolette said in a statement.

Adaptive Biotech also offers the ClonoSeq assay, a noninvasive next-generation sequencing-based test that predicts minimal residual disease in patients with blood cancers, and is developing a test for solid tumors. It acquired in vitro diagnostics firm Sequenta in January 2015.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.